[Pubmed] AChR Antibody-Positive Myasthenia Gravis
Posté : 14 mai 2024 12:00
Brain Nerve. 2024 May;76(5):613-620. doi: 10.11477/mf.1416202651.
ABSTRACT
Herein, we describe the mechanisms, diagnostic procedures, and treatment options for acetylcholine receptor (AChR) antibody-positive myasthenia gravis (MG). The upstream pathomechanism of this condition involves AChR-sensitized T cell-dependent B cell proliferation and the subsequent production of pathogenic autoantibodies. Downstream molecules include AChR antibodies that activate complement pathways, resulting in the destruction of motor endplates. We further introduce newly-developed molecular targeted drugs for the treatment of MG that aims to secure patients' health-related quality of life.
PMID:38741504 | DOI:10.11477/mf.1416202651
Source: https://pubmed.ncbi.nlm.nih.gov/3874150 ... t9+e462414